Results 261 to 270 of about 16,829,601 (344)

On a Modification of Certain Rank Tests

The Annals of Mathematical Statistics, 1963
openaire   +3 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Weak selection and stochastic processes limit the emergence of antigenic variants during household transmission of influenza A viruses. [PDF]

PLoS Pathog
Ries HJ, Lalli J, Florek KR, Barlow S, Goss M, Griesser R, Danz T, Uzicanin A, Temte J, Friedrich TC.   +9 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Structure-Aware Compound-Protein Affinity Prediction via Graph Neural Networks with Group Lasso Regularization. [PDF]

Comput Struct Biotechnol J
Shi Z, Wang Y, Weerawarna PM, Richardson TI, Zhang J, Wang Y, Huang K.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Asymmetric Cavovarus Deformity Presentation in Charcot-Marie-Tooth Disease. [PDF]

Foot Ankle Orthop
Requist MR, Peterson AC, Chrea B, Lenz AL.   +3 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Dopaminergic mechanisms of dynamical social specialization. [PDF]

Nature
Solié C, Nicolson A, Justo R, Layadi Y, Morin B, Batifol C, Reynolds LM, Le Borgne T, Fayad SL, Gulmez A, Rodriguez Quevedo Y, Allegret-Vautrot J, Centene Guglielmi G, de Chaumont F, Didienne S, Debray N, Hardelin JP, Girard B, Mourot A, Naudé J, Viollet C, Marti F, Delord B, Faure P.   +23 more
europepmc   +1 more source